Blinatumomab in induction therapy improves molecular response in untreated adults with Ph- B-cell precursor acute lymphoblastic leukemia
| Authors | |
|---|---|
| Year of publication | 2025 |
| Type | Article in Periodical |
| Magazine / Source | Haematologica |
| MU Faculty or unit | |
| Citation | |
| web | https://haematologica.org/article/view/11946 |
| Doi | https://doi.org/10.3324/haematol.2024.287062 |
| Keywords | Blinatumomab; acute lymphoblastic leukemia; Ph- B-cell precursor |
| Attached files | |
| Description | Blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, is effective in treating relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL), though most patients relapse despite achieving measurable residual disease (MRD) negativity. In the MRD setting, blinatumomab induced MRD negativity (MRDneg) in 78% of patients, with 85% achieving MRD <10-. Patients treated in their first complete remission (CR) showed better outcomes than those treated in later remissions. These findings support integrating blinatumomab into first-line polychemotherapy, as early MRD clearance significantly improves survival and reduces risk of relapse. |
| Related projects: |